Applied Therapeutics Inc. (APLT)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. (“Applied Therapeutics” or the "Company") (NASDAQ: APLT). The investigation concerns whether Applied Therapeutics and certain of its officers and/or directors have violated federal securities laws.


On or around May 13, 2019, Applied Therapeutics conducted its initial public offering (“IPO”), issuing 4 million shares of common stock priced at $10.00 per share.  On August 17, 2020, Applied Therapeutics disclosed that the U.S. Food and Drug Administration (“FDA”) has placed a partial clinical hold on the Company’s ACTION-Kids study evaluating the Company’s AT-007 product for the treatment of galactosemia.  The FDA cited the need for additional technical information related to ensuring that every participant in the study has access to the drug’s benefits.  On this news, Applied Therapeutics’ stock price fell $3.53 per share, or 12.07%, to close at $25.71 per share on August 17, 2020.


If you are aware of any facts relating to this investigation, or purchased Applied Therapeutics shares, you can assist this investigation by contacting the firm. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

© 2020 Bronstein, Gewirtz & Grossman, LLC

  • Twitter Social Icon
  • LinkedIn

BG&G is not affiliated to any of these companies. All respective trademarks are owned by the respective companies.